US 12,622,714

Application 19/353,713 · Granted May 12, 2026

Systems and methods for removing undesirable material within a circulatory system during a surgical procedure

Estimated expiration

August 6, 2028

1y 258d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Aug 6, 2008
+ 20 years
Aug 6, 2028
PTA +0d
Aug 6, 2028
No TD
—
Final
Aug 6, 2028

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
October 9, 2025
Earliest effective filing
August 6, 2008
Issue date
May 12, 2026
PTA
0 days
Base expiry (before PTA)
August 6, 2028

August 6, 2008 + 20 years = August 6, 2028

  • Continuation of application 19/303,491, filed Aug 19, 2025, issued as US 12,616,489
  • Continuation of application 19/013,019, filed Jan 8, 2025
  • Continuation of application 18/985,608, filed Dec 18, 2024
  • Continuation of application 18/942,929, filed Nov 11, 2024
  • Continuation of application 18/156,211, filed Jan 18, 2023, issued as US 12,446,904
  • Continuation of application 16/458,529, filed Jul 1, 2019, issued as US 11,589,880
  • Continuation of application 15/194,990, filed Jun 28, 2016, issued as US 10,383,983
  • Continuation of application 14/250,486, filed Apr 11, 2014, issued as US 9,402,938
  • Continuation of application 13/084,675, filed Apr 12, 2011, issued as US 8,734,374
  • Continuation-in-part of application 12/187,121, filed Aug 6, 2008, issued as US 8,075,510
  • Continuation-in-part of application 12/187,121, filed Aug 6, 2008, issued as US 8,075,510
  • Continuation of application 13/084,675, filed Apr 12, 2011, issued as US 8,734,374
  • Continuation-in-part of application 12/187,121, filed Aug 6, 2008, issued as US 8,075,510
  • Continuation of application 14/250,486, filed Apr 11, 2014, issued as US 9,402,938
  • Continuation of application 13/084,675, filed Apr 12, 2011, issued as US 8,734,374
  • Continuation-in-part of application 12/187,121, filed Aug 6, 2008, issued as US 8,075,510
  • Continuation of application 15/194,990, filed Jun 28, 2016, issued as US 10,383,983
  • Continuation of application 14/250,486, filed Apr 11, 2014, issued as US 9,402,938
  • Continuation of application 13/084,675, filed Apr 12, 2011, issued as US 8,734,374
  • Continuation-in-part of application 12/187,121, filed Aug 6, 2008, issued as US 8,075,510
  • Continuation of application 16/458,529, filed Jul 1, 2019, issued as US 11,589,880
  • Continuation of application 15/194,990, filed Jun 28, 2016, issued as US 10,383,983
  • Continuation of application 14/250,486, filed Apr 11, 2014, issued as US 9,402,938
  • Continuation of application 13/084,675, filed Apr 12, 2011, issued as US 8,734,374
  • Continuation-in-part of application 12/187,121, filed Aug 6, 2008, issued as US 8,075,510
  • Continuation of application 18/156,211, filed Jan 18, 2023, issued as US 12,446,904
  • Continuation of application 16/458,529, filed Jul 1, 2019, issued as US 11,589,880
  • Continuation of application 15/194,990, filed Jun 28, 2016, issued as US 10,383,983
  • Continuation of application 14/250,486, filed Apr 11, 2014, issued as US 9,402,938
  • Continuation of application 13/084,675, filed Apr 12, 2011, issued as US 8,734,374
  • Continuation-in-part of application 12/187,121, filed Aug 6, 2008, issued as US 8,075,510
  • Continuation of application 18/942,929, filed Nov 11, 2024
  • Continuation of application 18/156,211, filed Jan 18, 2023, issued as US 12,446,904
  • Continuation of application 16/458,529, filed Jul 1, 2019, issued as US 11,589,880
  • Continuation of application 15/194,990, filed Jun 28, 2016, issued as US 10,383,983
  • Continuation of application 14/250,486, filed Apr 11, 2014, issued as US 9,402,938
  • Continuation of application 13/084,675, filed Apr 12, 2011, issued as US 8,734,374
  • Continuation-in-part of application 12/187,121, filed Aug 6, 2008, issued as US 8,075,510
  • Continuation of application 18/985,608, filed Dec 18, 2024
  • Continuation of application 18/942,929, filed Nov 11, 2024
  • Continuation of application 18/156,211, filed Jan 18, 2023, issued as US 12,446,904
  • Continuation of application 16/458,529, filed Jul 1, 2019, issued as US 11,589,880
  • Continuation of application 15/194,990, filed Jun 28, 2016, issued as US 10,383,983
  • Continuation of application 14/250,486, filed Apr 11, 2014, issued as US 9,402,938
  • Continuation of application 13/084,675, filed Apr 12, 2011, issued as US 8,734,374
  • Continuation-in-part of application 12/187,121, filed Aug 6, 2008, issued as US 8,075,510
  • Continuation of application 19/013,019, filed Jan 8, 2025
  • Continuation of application 18/985,608, filed Dec 18, 2024
  • Continuation of application 18/942,929, filed Nov 11, 2024
  • Continuation of application 18/156,211, filed Jan 18, 2023, issued as US 12,446,904
  • Continuation of application 16/458,529, filed Jul 1, 2019, issued as US 11,589,880
  • Continuation of application 15/194,990, filed Jun 28, 2016, issued as US 10,383,983
  • Continuation of application 14/250,486, filed Apr 11, 2014, issued as US 9,402,938
  • Continuation of application 13/084,675, filed Apr 12, 2011, issued as US 8,734,374
  • Continuation-in-part of application 12/187,121, filed Aug 6, 2008, issued as US 8,075,510
  • PRO61/015,301 — Provisional — not used for base term
  • PRO61/015,301 — Provisional — not used for base term
  • PRO61/015,301 — Provisional — not used for base term
  • PRO61/015,301 — Provisional — not used for base term
  • PRO61/015,301 — Provisional — not used for base term
  • PRO61/015,301 — Provisional — not used for base term
  • PRO61/015,301 — Provisional — not used for base term
  • PRO61/015,301 — Provisional — not used for base term
  • PRO61/015,301 — Provisional — not used for base term
  • PRO61/015,301 — Provisional — not used for base term
  • PRO61/015,301 — Provisional — not used for base term

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 19/353,713 · US 12,622,714

PatentReply compiles the prosecution history behind US 12,622,714: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US12622714

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.